License Agreement to Development and Commercialize Azithromycin Ophthalmic Solution Using DuraSite® in Japan | News | SENJU Pharmaceutical

News

June 11, 2014

License Agreement to Development and Commercialize Azithromycin Ophthalmic Solution Using DuraSite® in Japan

 

Senju Pharmaceutical Co., Ltd. (“Senju”) (Headquarters: Osaka, President: Yukoh Yoshida) and InSite Vision Incorporated (“InSite”) (Headquarters: California, USA, CEO: Timothy Ruane) today announced that they have entered into a license agreement to develop and commercialize InSite’s azithromycin ophthalmic solution using the DuraSite® in Japan.

 

Under the terms of the agreement, Senju will make an upfront payment and development milestone payments to InSite. After commercialization, Senju will also pay royalties based on net sales in Japan.

 

In the U.S., InSite’s azithromycin ophthalmic solution leveraging the DuraSite® platform is currently marketed under the brand name of AzaSite® (azithromycin ophthalmic solution) 1% by Akorn Inc. for the treatment of bacterial eye infections,

 

About InSite Vision

InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite platform technologies. The DuraSite® and DuraSite® 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs.

 

Back to the list